Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FULIRI Regimen Combined With Targeted Therapy for First-line Conversion Treatment of Colorectal Cancer Liver Metastases
NCT07515963Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in colorectal cancer (CRC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Objective Response Rate at 1 year. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07515963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515963.